Haleon plc is a global consumer health company headquartered in the United Kingdom, created in 2022 through the demerger of GSK’s consumer healthcare business (previously a joint venture with Pfizer). The company develops, manufactures, and markets over-the-counter (OTC) self-care products across oral health, pain relief, respiratory and cold/flu, digestive health, and vitamins, minerals and supplements (VMS). Its portfolio includes brands such as Sensodyne, Voltaren, Panadol, Centrum, Theraflu, Otrivin, and Polident, sold in numerous international markets.
For the chemicals and materials ecosystem, Haleon’s activities involve formulation R&D and large-scale production using active pharmaceutical ingredients, excipients, flavors/aromas, and diverse packaging substrates (plastics, glass, aluminum, and fiber). The company operates global supply chains and collaborates with contract manufacturers and packaging suppliers, with a focus on product quality, regulatory compliance, and packaging sustainability, including increased use of recyclable and lower-carbon materials.
None yet. When a new project in the record names Haleon as owner, partner or investor, it shows here.
The agreement reserves future volumes of plant-based polymer PEF, enhancing sustainable packaging innovation and supporting the development of high-performance solutions.
